Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Etsuro Hatano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3407-1918; OpenAlex author ID A5056173852, A5132700995, A5149864426. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
117
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: 7 papers · 2024: 2 papers · 2025: 6 papers · 2026: 6 papers

Papers 25

  1. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  2. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  3. Prognostic Impact of Major Pathologic Response After Preoperative Treatment in Resected Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Retrospective S… Last author DOI 10.1097/sla.0000000000007052↗
  4. Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci206371↗
  5. Comparison of Comprehensive Serum miRNA Sequencing and Apolipoprotein A2 Isoforms for Early Detection of Pancreatic Cancer. Co-author DOI 10.3390/cancers18071177↗
  6. Pancreatic Neuroendocrine Tumor with Acinar Pattern Mimicking Pancreatic Ductal Adenocarcinoma: A Case Report. Last author DOI 10.70352/scrj.cr.26-0184↗
  7. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  8. Neoadjuvant chemoradiotherapy using moderately hypofractionated intensity-modulated radiotherapy for borderline resectable pancreatic cancer : Outcomes and pro… Co-author DOI 10.1007/s00066-025-02433-9↗
  9. Proposing oligo-recurrence criteria in pancreatic ductal adenocarcinoma: A stratified analysis of locoregional treatment benefits. Last author DOI 10.1016/j.pan.2025.04.012↗
  10. Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Co-author DOI 10.1172/jci177533↗
  11. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  12. Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity-Modulated Radiotherapy Versus Upfront Surgery for Resectable Pancreatic Cancer: A Ret… Last author DOI 10.1245/s10434-025-16956-z↗
  13. Reduction of butyrate-producing bacteria in the gut microbiome of Japanese patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.09.002↗
  14. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  15. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  16. Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A pros… Last author DOI 10.1002/cam4.6470↗
  17. Association between patient's age and the utility of prognostic markers after pancreaticoduodenectomy for pancreatic cancer. Last author DOI 10.1016/j.asjsur.2022.10.009↗
  18. Brg1 controls stemness and metastasis of pancreatic cancer through regulating hypoxia pathway. Co-author DOI 10.1038/s41388-023-02716-4↗
  19. Preoperative Endoscopic Minor Papilla Sphincterotomy for Pancreas Divisum in a Patient with Pancreatic Cancer Who Underwent Laparoscopic Distal Pancreatectomy. Last author DOI 10.1245/s10434-023-13975-6↗
  20. Is 6 Months the Optimal Duration of Adjuvant Chemotherapy for Pancreatic Cancer? Last author DOI 10.21873/cdp.10258↗
  21. Autophagy Inhibition Increased Sensitivity of Pancreatic Cancer Cells to Carbon Ion Radiotherapy. Co-author DOI 10.33594/000000639↗
  22. Impact of the aberrant right hepatic artery on local recurrence of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Co-author DOI 10.1016/j.surg.2022.02.010↗
  23. Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase… Last author DOI 10.1186/s12885-022-09244-6↗
  24. Establishment of patient-derived organoids and a characterization-based drug discovery platform for treatment of pancreatic cancer. Last author DOI 10.1186/s12885-022-09619-9↗
  25. Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6077-y↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshihiko Masui · 12 shared papers, 2022–2026 · strength 2.11
  2. Kazuyuki Nagai · 11 shared papers, 2022–2026 · strength 2.10
  3. Akihisa Fukuda · 10 shared papers, 2022–2026 · strength 1.80
  4. Kei Yamane · 6 shared papers, 2023–2026 · strength 1.26
  5. Hiroshi Seno · 6 shared papers, 2022–2026 · strength 1.06
  6. Michio Yoshimura · 5 shared papers, 2022–2025 · strength 0.89
  7. Shintaro Yagi · 5 shared papers, 2017–2026 · strength 0.81
  8. Kei Iimori · 4 shared papers, 2024–2026 · strength 0.77
  9. Asahi Sato · 4 shared papers, 2022–2026 · strength 0.72
  10. Takahisa Maruno · 4 shared papers, 2023–2026 · strength 0.70
  11. Makoto Sono · 4 shared papers, 2023–2026 · strength 0.70
  12. Seiko Hirono · 4 shared papers, 2023–2026 · strength 0.64
  13. Takahiro Iwai · 3 shared papers, 2025 · strength 0.62
  14. Munenori Kawai · 3 shared papers, 2025–2026 · strength 0.60
  15. Tsutomu Fujii · 3 shared papers, 2025–2026 · strength 0.58
  16. Naoki Ikenaga · 3 shared papers, 2024–2026 · strength 0.54
  17. Michiaki Unno · 3 shared papers, 2024–2026 · strength 0.53
  18. Osamu Araki · 3 shared papers, 2023–2026 · strength 0.53
  19. Motoyuki Tsuda · 3 shared papers, 2023–2026 · strength 0.53
  20. Dieter Saur · 3 shared papers, 2023–2026 · strength 0.53
  21. Manabu Kawai · 3 shared papers, 2023–2026 · strength 0.52
  22. Yuichiro Uchida · 3 shared papers, 2022–2026 · strength 0.51
  23. Sohei Satoi · 3 shared papers, 2023–2025 · strength 0.48
  24. Masashi Kanai · 3 shared papers, 2022–2025 · strength 0.48
  25. Takashi Mizowaki · 3 shared papers, 2022–2025 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.